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Objective: This study evaluates the safety and effectiveness of a unique composite thoracic endovascular aneurysm repair
(TEVAR) construct (proximal stent graft and distal bare metal stent) for the treatment of patients with complicated type
B aortic dissection (cTBAD).
Methods: In this prospective, single-arm, multicenter study, patients with cTBAD were treated with an endovascular
system consisting of proximal TX2 thoracic stent grafts and distal bare metal dissection stents (Zenith Dissection
Endovascular System; Cook Medical, Bloomington, Ind). Indications for enrollment were branch vessel malperfusion,
impending rupture, aortic diameter >40 mm, rapid aortic expansion, and persistent pain or hypertension despite
maximum medical therapy. One-year follow-up results, including clinical and radiographic (computerized tomography
[CT] and X-ray) evaluation, were available for this report.
Results: Ten centers enrolled 40 patients (70% men; mean age 58 years old) between December 2007 and August 2009.
The onset of symptoms was acute (<14 days) in 24 patients (60%), subacute (15-30 days) in six patients (15%), and
chronic (31-90 days) in 10 patients (25%); the overall mean time from symptom onset to treatment was 20 days (range,
0-78 days). A majority of patients (77.5%; 31 of 40 patients) presented with impending aortic rupture (indicated by
periaortic effusion/hematoma) or branch vessel malperfusion. Seven combinations of stent grafts and dissection stents
were used, and all devices were successfully deployed and patent. The 30-day mortality rate was 5% (2 of 40); two deaths
occurred after 30 days, leading to a 1-year survival rate of 90%. Two deaths, occurring at 11 and 81 days postprocedure,
respectively, were secondary to aortic rupture. Morbidity occurring within 30 days included stroke (7.5%), transient
ischemic attack (2.5%), paraplegia (2.5%), retrograde progression of dissection (5%), and renal failure (12.5%). Additional
morbidity after 30 days included one case of retrograde progression of dissection and one case of renal failure. None of
the patients with renal failure became dialysis-dependent. Four patients (10%) underwent secondary interventions within
1 year. Favorable aortic remodeling was observed during the course of follow-up, indicated by an increase in the true
lumen size and a concomitant decrease in the false lumen size along the dissected aorta, with completely thrombosed
thoracic false lumen observed in 31% of patients at 12 months as compared to 0% at baseline.
Conclusions: Initial data with a composite TEVAR construct have demonstrated favorable clinical and anatomic results.
Continued enrollment and long-term data are needed to assess the overall effectiveness of this treatment strategy. (J Vasc
Surg 2012;55:629-40.)
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March 2012630 Lombardi et alThe management of complicated type B aortic dissec-
tion (cTBAD) has been transformed with the introduction
of commercially available devices designed for thoracic
endovascular aneurysm repair (TEVAR).1 Entry tear cov-
erage with TEVAR and redirection of thoracic aortic flow
entirely through the true lumen have been the hallmarks
of endovascular repair. Compared with a 30-day mortality
of nearly 27% with open repair,2 studies have shown an
improved early mortality of approximately 10% with endo-
vascular repair.3,4 However, the natural history of cTBAD
after endoluminal repair is still poorly understood with
scarce long-term follow-up. Multiple adjunctive proce-
dures at the initial treatment and during follow-up are
usually necessary, and no clear endpoint in therapy has yet
been defined for patients with residual false lumen flow.
Other challenges with aortic dissection treatment are the
anatomic variability from patient to patient and difficulties
in making prompt diagnosis. Once treated with TEVAR,
persistent obstruction of distal branch vessels despite entry
tear coverage as well as persistent false lumen flow with late
aneurysm formation can be problematic.
The use of bare metal stents to promote true lumen
expansion after entry tear coverage with TEVAR was first
described by Mossop and Nixon.5 Nienaber et al6 subse-
quently described 12 instances (from a series of 100 pa-
tients), where persistent true lumen collapse was present
after endograft coverage of the proximal entry tear and
were treated with bare metal scaffolding stents. They con-
cluded that scaffolding the distal thoracoabdominal aorta
restored flow to malperfused branch vessels and induced
positive aortic remodeling. In addition, re-expansion of the
true lumen with a “scaffolding” stent can facilitate adjunc-
tive intervention for obstructed branch vessels at the initial
procedure and in follow-up.
The Zenith Dissection Endovascular System (Cook
Medical, Bloomington, Ind) is a dual-construct, pathology-
specific device that provides proximal sealing of the primary
entry tear with a covered stent graft and distal support of
the dissected true lumen with bare metal stents. In their
single-center experience, Melissano et al7 reported good
short-term results with this system in 11 patients. The
current study reports 12-month’s results from the Study of
Thoracic Aortic Type B Dissection Using Endoluminal
Repair trial (STABLE), a prospective, nonrandomized,
multicenter study that evaluates the safety and performance
of the Zenith Dissection Endovascular System for the treat-
ment of patients with cTBAD and anatomy suitable for
endovascular repair.
METHODS
Study design. The STABLE trial is a prospective,
nonrandomized, multicenter clinical trial conducted at in-
stitutions in the United States, Europe, and Australia. The
study’s endpoint was 30-day mortality; other outcomes
included clinical utility, adverse events, aortic remodeling,
and device performance. The study was performed accord-
ing to the Declaration of Helsinki II. Ethical approval was abtained from the relevant ethics committee at each insti-
ution, and all patients signed an informed consent.
Patient eligibility. Patients with cTBAD that war-
anted surgical intervention or did not respond well to
edical management were included in the study. The
ndications for enrollment included branch vessel obstruc-
ion/compromise, impending rupture as evidenced by
eriaortic effusion/hematoma, resistant hypertension, per-
istent pain/symptoms, or aortic growth 5 mm within 3
onths (or transaortic diameter 40 mm). Patients were
xcluded if they met any of the general, medical, or ana-
omic exclusion criteria (Table I). All enrolled patients
eceived treatment within 3 months of onset of dissection
ymptoms.
Device description and implantation procedure.
he Zenith Dissection Endovascular System comprises two
odular components: the Zenith TX2 thoracic aortic an-
urysm Endovascular Graft with Pro-Form (same as the
roximal component of the two-piece TX2 device for the
reatment of thoracic aneurysms8) and the Zenith Dissec-
ion Endovascular Stent (Fig 1).
Preoperative imaging studies, including multiplanar
omputerized tomography (CT), were used for selecting
he proximal and distal landing zones and for device sizing.
enerally, 0 to 10% oversizing of the stent graft based on
he proximal landing zone diameter is recommended.
Following deployment of the TX2 stent graft compo-
ent to cover the primary entry tear, deployment of the
are stent component was recommended if branch vessel
bstruction or false lumen perfusion persisted. Bare stent
lacement may not be necessary in patients for whom all of
he following were applicable: (1) no signs or symptoms
f obstructed/compromised branch vessels (if patient
as included in the study for branch vessel obstruction/
ompromise); (2) systolic pressure gradient 20 mm Hg
etween the aortic root and a distal obstructed aortic
egment/vessel (if patient was included in the study for
ranch vessel obstruction/compromise); and (3) no false
umen flow through secondary re-entry tears. There was no
imit to the number or the distal extent of dissection stents
sed; the decision to use the dissection stent and on the
evice combination was ultimately based on physician clin-
cal judgment. Molding balloon angioplasty within the
X2 stent graft was optional, whereas it was discouraged
ithin the bare dissection stent. Adjunctive stent placement
or occluded or obstructed branch vessels was performed as
ecessary at the discretion of the operating physician.
Patient follow-up. Follow-up CT scans, abdominal
adiographs, physical examinations, and laboratory stud-
es were obtained before discharge, at 1, 6, and 12
onths, and yearly thereafter up to 5 years. Imaging
tudies were evaluated by each investigative site and an
ndependent core laboratory. Unless indicated other-
ise, data reported herein reflect the results from the
ore laboratory analysis.
Data analysis. Data were managed by a centralized
ata-coordinating center, MED Institute, Inc. Statistical
nalyses were performed using SAS for Windows (release
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Volume 55, Number 3 Lombardi et al 6319.1 or higher; SAS Institute, Cary, NC) or other widely
accepted statistical software. Continuous variables are re-
ported as means and SDs unless otherwise noted and cate-
gorical variables are reported as percentages. A Kaplan-
Meier analysis was performed to estimate freedom from
all-cause mortality through 1 year. An aortic remodeling
analysis was carried out using a general linear model to
account for the procedure effect over a 1-year follow-up. P
values .05 were considered significant.
RESULTS
Ten centers enrolled 40 patients between December
2007 and August 2009. This manuscript reports
follow-up results through 1 year after the initial proce-
dure, and these results reflect data received as of January
7, 2011.
Preprocedural patient characteristics. The majority
Table I. Exclusion criteria
General exclusion criteria
Age 18 years;
Other medical condition (eg, cancer, congestive heart failure) th
confound the results, or is associated with limited life expecta
Pregnant, breastfeeding, or planning on becoming pregnant wit
Unwilling or unable to comply with the follow-up schedule;
Inability or refusal to give informed consent; or
Simultaneously participating in another investigative device or d
of any previous study at least 30 days before enrollment in th
Medical exclusion criteria
Frank rupture;
Diagnosed or suspected congenital degenerative connective tiss
Systemic infection (eg, sepsis);
Allergy to stainless steel, polyester, solder (tin, silver), polyprop
Untreatable reaction to contrast, which, in the opinion of the in
Surgical or endovascular AAA repair within 30 days before or af
Previous placement of a thoracic endovascular graft;
Prior open repair involving the descending thoracic aorta, inclu
Interventional and/or open surgical procedures (unrelated to d
Onset of symptoms 3 months.
Anatomic exclusion criteria
Dissection of aorta proximal to left subclavian (either primary e
Proximal landing zone length measuring 20 mm between the
(covering left subclavian is acceptable, except in patients with
dominant vertebral off of the subclavian);
Distal landing zone length measuring 20 mm between celiac
Proximal landing zone diameter for stent graft, measured outer
24 mm or 38 mm;
Aortic arch radius of curvature 35 mm;
Distal landing zone diameter for stent graft, measured outer-wa
24 mm (estimate based on transaortic diameter) or 38 mm
Diameter measured outer-wall to outer-wall on a sectional imag
transaortic diameter) or 38 mm (estimate based on true lum
bare stent device is intended;
Prohibitive angulation in segments of vessel into which deploym
mm, or localized angle 35 degrees);
Both iliac arteries having prohibitive tortuosity, calcification, oc
on a sectional image, that are not conducive to placement of
Prohibitive calcification, occlusive disease, or angulation in inten
Circumferential thrombus in region of intended proximal landin
Inability to preserve the left common carotid artery and celiac tr
Aneurysm or angulation in the distal thoracic aorta that would p
AAA, Abdominal aortic aneurysm.of patients were men (70%; 28 of 40) and the mean age was a8 years old (range, 35-83 years old). Patient characteris-
ics, including preoperative conditions and risk assessment
re presented in Table II. Anatomic features of the dis-
ected aorta are presented in Fig 2.
The mean time from symptom onset to treatment was
0 days (range, 0-78 days). According to the definitions by
hite et al,9 the onset of symptoms was acute (14 days)
n 24 patients (60%), subacute (15-30 days) in six patients
15%), and chronic (31-90 days) in 10 patients (25%).
ndications for treatment in the overall patient group and
y dissection symptom status are presented in Table III. In
he overall patient group, the median number of indica-
ions was three per patient (range, 1-5). A majority of
atients (77.5%; 31 of 40) presented with impending aortic
upture (indicated by periaortic effusion or hematoma;
0%; 8 of 40) and/or branch vessel malperfusion (obstruc-
ion/compromise based on clinical and/or imaging evalu-
ay cause the patient to be noncompliant with the protocol,
ie, less than 2 years);
4 months;
tudy. (The patient must have completed the primary endpoint
y.)
ease (no Marfan’s or Ehlers-Danlos syndrome);
nitinol, or gold;
gator, cannot be adequately premedicated;
ssection repair;
he supra-renal aorta and/or arch;
ion) within 30 days before or after dissection repair; or
ear or most proximal extent of dissection);
ommon carotid and most proximal extent of dissection
inant vertebral off of the arch in the region of the subclavian or a
rimary entry tear;
to outer-wall on a sectional image or multiplanar reconstruction,
uter-wall on a sectional image or multiplanar reconstruction,
timate based on true lumen diameter);
ultiplanar reconstruction, 24 mm (estimate based on
iameter), for any segment of vessel into which deployment of
f bare stent device is intended (eg, radius of curvature 55
e disease, or arterial diameter, measured inner-wall to inner-wall
troducer sheath (use of access conduit permitted);
proximal landing zone;
ne;
or
de advancement of the introduction system.at m
ncy (
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March 2012632 Lombardi et alvessel obstruction/compromise involved the gastrointesti-
nal system (five of 27), kidneys (17 of 27), spinal cord (one
of 27), and limbs (15 of 27).
Procedural results. Most patients received general
anesthesia (92.5%; 37 of 40) during the procedure. Mean
procedure time (from incision to closure) was 163 minutes
(range, 40-397 minutes), and mean blood loss was 222 mL
(range, 0-800 mL). Average intensive care unit stay was 5.9
days (range, 0-44 days), and overall length of hospital stay
was 13.6 days (range, 3-44 days).
Seven combinations of TX2 stent graft and dissection
stent were used (Fig 3). All 40 patients received one or
more TX2 stent grafts. The left subclavian artery was cov-
ered in 25 patients (62.5%; the site assessment was used in
four patients where imaging could not be adequately ana-
lyzed by the core laboratory), with carotid-subclavian by-
pass performed in three patients, and carotid-carotid bypass
performed in three patients. Thirty-nine patients received
at least one dissection stent (multiple dissection stents used
in 14 patients); one patient did not receive a dissection stent
because of satisfactory results following placement of a TX2
stent graft.
During the initial procedure, adjunctive stent place-
Fig 1. Illustration of the Zenith Dissection Endovas
aneurysm Endovascular Graft with Pro-Form and the Ze
proximal TX2 endovascular graft and two distal dissec
dissection. The TX2 endovascular graft is available in a v
nontapered configurations. The right panel shows a clos
multiple (four, six, or eight) self-expanding stainless ste
suture. The dissection stent was initially available in one
mm). A smaller diameter dissection stent (36 mm) was in
been used in patients included in this study.ment was performed in nine patients for 13 branch vessels tsix iliac arteries, six renal arteries, and one superior mesen-
eric artery). Examples of adjunctive stent placement are
hown in Fig 4. Other adjunctive devices used during the
nitial procedure included molding balloons in 14 patients,
mbolization coils in one patient (to occlude the distal false
umen and a lumbar artery), and an Amplatzer occluder
AGA Medical Corporation, Plymouth, Minn) in one pa-
ient (to occlude the left subclavian artery after carotid-
ubclavian bypass). In one patient, endovascular fenestra-
ion was performed in both iliac arteries and the abdominal
orta because of limited flow and unsuccessful attempts to
annulate the true lumen; subsequently, stents were placed
xtending from the distal infrarenal aorta to the common
liac arteries to assure adequate perfusion of the bilateral
ower extremities. Adjunctive cerebrospinal fluid drainage
as performed in 13 patients (32.5%).
All TX2 stent grafts and dissection stents were deployed
uccessfully. In one instance, pulling back the sheath from
he dissection stent was reported as “somewhat difficult,”
ut the stent was deployed successfully without any clinical
equelas. At completion of the procedures, all deployed
omponents were patent and without significant kinks.
ore laboratory review of angiograms showed no type I or
System, comprising the Zenith TX2 thoracic aortic
issection Endovascular Stent. The left panel shows one
stents deployed in a model of Type B thoracic aortic
y of standard stock sizes and in tapered (by 4 mm) and
age of the bare metal dissection stent, which consists of
tent segments sewn end-to-end with braided polyester
eter (46 mm) and multiple lengths (82, 123, and 164
ced later; however, this 36 mm dissection stent has notcular
nith D
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ariet
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troduype III entry flow at completion of the procedure.
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Volume 55, Number 3 Lombardi et al 633Patient follow-up. Of patients eligible for follow-up,
clinical evaluation was performed for 35 of 38 patients
(92.1%) at 30 days and 34 of 36 patients (94.4%) at 1 year.
Follow-up imaging with adequate quality for core labora-
tory analysis was available for 34 of 38 patients (89.5%) at
Table II. Preprocedural patient characteristics
Preoperative condition % (n/N)
Cardiovascular
Previous MI 5.0 (2/40)
Previous symptomatic CHF 2.5 (1/40)
LVEF 20% 0 (0/36)
Previous diagnosis of coronary artery
disease 7.9 (3/38)
Previous diagnosis of cardiac arrhythmia 2.5 (1/40)
Vascular
Thromboembolic event 5.0 (2/40)
Peripheral vascular disease 7.5 (3/40)
Family history of aneurysm or dissection 6.3 (2/32)
Patient history of aneurysm or
dissection 10.8 (4/37)
Hypertension 92.5 (37/40)
Previous thoracic surgery or thoracic
trauma 0 (0/39)
Bleeding diathesis or uncorrectable
coagulopathy 0 (0/40)
Previous aortic fenestration 5.0 (2/40)
Chronic obstructive pulmonary disease 2.6 (1/39)
Renal failure requiring dialysis 5.0 (2/40)
Diabetes 7.5 (3/40)
Previous diagnosis of sepsis 0 (0/40)
Previous diagnosis of cancer 2.5 (1/40)
Neurologic
Previous diagnosis of cerebrovascular
disease 15.0 (6/40)
Previous endarterectomy 0 (0/40)
Substance use
Excessive alcohol use 8.1 (3/37)
Smoking 58.3 (21/36)
Risk assessment Median (range)
ASA classa 3 (2-4), n  38
SVS-ISCVS scoreb
Diabetes 0 (0-2), n  40
Smoking 0 (0-3), n  40
Hypertension 0 (0-3), n  40
Hyperlipidemia 0 (0-3), n  40
Cardiac 0 (0-3), n  40
Carotid 0 (0-2), n  40
Renal 0 (0-3), n  40
Pulmonary 0 (0-2), n  40
ASA, American Society of Anesthesiologists; CHF, congestive heart failure;
LVEF, left ventricular ejection fraction; MI, myocardial infarction; SVS-
ISCVS, Society for Vascular Surgery/International Society for Cardiovascu-
lar Surgery.
aAmerican Society of Anesthesiologists (ASA) classification: 1, healthy pa-
tient for elective operation; 2, patient with mild systemic disease that limits
activity but is not incapacitating; 3, patient with severe systemic disease that
is a constant threat to life, limits activity, but is not incapacitating; 4, patient
with incapacitating systemic disease that is a constant threat to life; and 5,
moribund patient not expected to live 24 hours without operation.
bThe Society for Vascular Surgery/International Society for Cardiovascular
Surgery (SVS/ISCVS) risk factor score ranges from 0 (no risk factors) to 3
(severe risk factors) for each of eight domains.30 days and 33 of 36 patients (91.7%) at 1 year. mMortality and aortic rupture. The 30-day mortality
ate was 5% (two of 40). One patient (enrolled with persis-
ent pain and obstruction/compromise of both renal arter-
es, both visceral arteries, and the right common iliac artery)
ied 11 days postprocedure from aortic rupture in the
etting of chronic hypertension. This patient presented
ith renal failure at enrollment and experienced a stroke
ntraoperatively. Autopsy results indicated false lumen rup-
ure in the superior descending thoracic aorta, with an
ntact intimal flap between the true and false lumens. Post-
rocedural CT showed a partially thrombosed thoracic false
umen and a patent abdominal false lumen perfused by
ollateral flow. The second patient (enrolled with obstruc-
ion/compromise of the right renal artery, aortic growth
5 mm within 3 months, and transaortic diameter 40
m) died suddenly at home 29 days postprocedure of
nknown reasons. Postprocedural CT showed patent and
ntact devices, a thrombosed thoracic false lumen, and a
atent abdominal false lumen perfused by collateral flow;
linical examination at discharge (at 10 days) did not show
ain, discomfort, or other symptoms.
Two additional patients died between 31 and 365 days.
Kaplan-Meier analysis of all-cause mortality (Fig 5) esti-
ates a 90% survival rate at 1 year. One patient (enrolled
ith persistent pain, aortic growth 5 mm within 3
ig 2. Distribution of the primary tear, proximal extent, and
istal extent of dissection. CIA, Common iliac artery; EIA, exter-
al iliac artery; IIA, internal iliac artery; LRA, left renal artery; LSA,
eft subclavian artery; RRA, right renal artery; SMA, superior
esenteric artery.onths, and transaortic diameter 40 mm) died 81 days
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March 2012634 Lombardi et alpostprocedure from complications of right coronary artery
occlusion and aortic rupture with left hemothorax due
to aortic rupture. The false lumen ruptured in the mid-
descending thoracic aorta, adjacent to the covered stent
graft, and the intimal flap between the true and false lumen
was intact. CT imaging at 30 days showed partially throm-
bosed false lumens in both the thoracic and abdominal
aorta perfused by collateral flow. The second patient (en-
rolled with uncontrolled hypertension, persistent pain, and
transaortic diameter 40 mm) died 137 days after the
initial procedure due to non-Hodgkin lymphoma; this
death was determined by an independent clinical events
committee to be unrelated to the dissection repair.
Overall, within 1 year, two patients experienced aortic
rupture and died; both patients presented in the acute
phase.
Adverse events. Adverse events occurring within 30
days and between 31 and 365 days are summarized by
organ systems (Table IV, online only).
Transient renal failure (that did not require permanent
dialysis) occurred in five patients (12.5%) within 30 days
and in one patient (2.6%) between 31 and 365 days. All five
patients experiencing renal failure within 30 days had pre-
Table III. Indications for treatment in all patients and in
status
Criterion, % (n/N)
Acute
(n  24)
Branch vessel obstruction/compromise 75.0% (18/2
Peri-aortic effusion/hematomaa 29.2% (7/24
Resistant hypertension 62.5% (15/2
Persistent pain/symptoms 87.5% (21/2
Transaortic growth 5 mm within 3 months
(or transaortic diameter 40 mm) 33.3% (8/24
aIndicative of threatened rupture.
Fig 3. Device combinations used in this study. TX2 refe
metal dissection stent.existing renal insufficiency, renal failure, or renal artery lbstruction/compromise. Two patients underwent sec-
ndary interventions of renal artery stent placement within
0 days. None of the patients with renal failure required
ermanent dialysis.
All neurologic events occurred within 30 days and
ncluded stroke in three patients (7.5%; one patient also
xperienced paraplegia), transient ischemic attack (TIA) in
ne patient (2.5%), and paraparesis/spinal cord shock in
ne patient (2.5%). Among the three patients who suffered
trokes, one patient died 11 days postprocedure from aortic
upture, one patient (who also experienced paraplegia) was
ischarged to and remained in a skilled nursing facility, and
ne patient had mild residual deficit at 12 months. During
he initial procedure, all three patients with strokes had the
eft subclavian artery (LSA) covered without revasculariza-
ion.
Retrograde progression of dissection was reported in
wo patients (5%) within 30 days and one patient (2.6%)
etween 31 and 365 days. In two of the three patients, the
tent graft was placed without a sufficient proximal landing
one. Two patients underwent secondary interventions
aortic valve replacement and ascending aortic arch repair
n one patient, and proximal extension placement following
nt subgroups with acute, subacute, and chronic symptom
Subacute Chronic Overall
(n  6) (n  10) (n  40)
50.0% (3/6) 60.0% (6/10) 67.5% (27/40)
16.7% (1/6) 0% (0/10) 20.0% (8/40)
83.3% (5/6) 60.0% (6/10) 65.0% (26/40)
50.0% (3/6) 70.0% (7/10) 77.5% (31/40)
66.7% (4/6) 90.0% (9/10) 52.5% (21/40)
the proximal TX2 stent graft and stent refers to the barepatie
4)
)
4)
4)
)rs toeft carotid-subclavian bypass in one patient), and the third
JOURNAL OF VASCULAR SURGERY
Volume 55, Number 3 Lombardi et al 635Fig 4. Adjunctive stent placement during the initial procedure. A, The right renal artery originally perfused by the
false lumen (left panel) was treated with a stent inserted from the true lumen through the uncovered dissection stent
(right panel). This patient also underwent coil embolization of the distal false lumen and a lumbar artery. B, The
dissected right common iliac artery (left panel) was treated with placement of two stents (right panel).Fig 5. Kaplan-Meier analysis of all-cause mortality. The vertical bars represent 95% confidence intervals, and the dots
represent censored data.
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March 2012636 Lombardi et alpatient did not require any reintervention. All three pa-
tients were alive at the last follow-up.
The majority of patients with the above adverse events
(five of six with renal failure, four of four with strokes and
TIA, and two of three with retrograde dissection) pre-
sented dissection symptoms in the acute phase.
Secondary interventions. No conversion to open sur-
gical repair occurred within 1 year. As shown in Table V,
four patients (10%) underwent a total of six secondary
interventions remote from the initial procedure.
Device performance. No device integrity issues re-
lated to the dissection stent were observed. In two patients,
component separation or device migration necessitated
secondary interventions. In one patient, increased spacing
between the stent graft and the dissection stent was ob-
served, and a secondary tear was noted between compo-
nents. Intimal flap disruption caused by molding balloon
angioplasty during the initial procedure may have contrib-
uted to the component separation. This patient underwent
placement of an extension component to seal the secondary
tear at 7 months. The second patient experienced caudal
migration of the stent graft, which was placed in a dissected
segment of the descending thoracic aorta without a suffi-
cient proximal landing zone. This patient also developed
retrograde progression of the dissection and underwent
placement of a proximal extension component at 10
months. In addition, the core laboratory noted radio-
graphic evidence of migration of the dissection stent in one
patient and the stent graft in one patient. No clinical
sequelas were observed in these two patients.
Entry flow was classified in Fig 6 (online only). As
shown in Table VI (online only) only one patient (one of
32; 3.1%) had a proximal type I entry flow, which was first
noted postprocedure and decreased significantly at 6 and
12 months. Both the thoracic and abdominal false lumens
were also perfused via collateral vessels. In this patient, the
thoracic false lumen remained stable in size and the abdom-
inal false lumen showed a slight increase (5 mm) in size at
Table V. Summary of 4 patients who underwent secondar
Patient Days postprocedure Reason for intervention
1 1 Liver and gall bladder ischemia
20 Renal failure requiring dialysis
224 Persistent perfusion of the false
lumenb
2 18 Renal failure requiring dialysis
3 35 Retrograde dissection
4 324, 326 Migration and retrograde
dissection
aIn this patient, occlusion of the true lumen at the origin of the celiac arter
laboratory analysis. During the procedure, attempts to cannulate the celiac a
stent at the junction of overlap with the TX2 component may have caused
cannulation the celiac artery.
bLoss of overlap between the TX2 stent graft and the dissection stent was obs
tear noted in the space between the components. The use of the molding b12 months compared to the corresponding postprocedure ialues. No patient experienced a type III entry flow. During
ollow-up, direct flow into the false lumen was mainly via
atent collateral vessels and through secondary tears.
Aortic remodeling. A general linear model was used
o estimate the effects of the dissection treatment on the
izes (diameters and areas) of the true lumen and false
umen (Fig 7). From baseline to postprocedure, the true
umen along the aorta expanded significantly (P  .005),
orresponding to a significant decrease in the false lumen
ize (P  .001; the only exception was an insignificant P
alue for the area of the descending thoracic aorta). From
ostprocedure to the 12-month follow-up, the true lumen
ize continued to increase (P  .05) and the false lumen
ize continued to decrease (P  .05) in the descending
horacic aorta, whereas the lumen sizes remained relatively
table (defined as no significant increase or decrease) at
ore distal locations (P values were not significant).
Qualitative assessments of false lumen status are sum-
arized in Table VII. A Cochrane Armitage Trend test
ndicated a significant increase in the percentage of patients
ith a completely thrombosed false lumen in the thoracic
orta (P .001), and a concomitant, significant decrease in
he percentage of patients with a patent false lumen in the
bdominal aorta (P  .001). Examples of early true lumen
xpansion and continued aortic remodeling are shown in
ig 8.
ISCUSSION
The 40 patients included in this prospective, multi-
enter study represent a difficult patient subgroup with
TBAD. The 30-day mortality (5%) is in line with that
eported in most large series.9-11 In particular, a report by a
ultidisciplinary subcommittee of the Society for Vascular
urgery (SVS) Outcomes Committee reported a 30-day
oint-estimate mortality of 10.8% as a performance goal for
ingle-arm investigational device exemption trials evaluat-
ng endovascular treatment of cTBAD.9 This report in-
luded data collected on 99 patients from five independent
ervention
Type of intervention Mortality
Cholecystectomy and ileohepatic bypass Alive at 12 months
Angioplasty and renal artery stenting
Placement of extension component to
seal secondary tear
Renal artery stenting Alive at 12 months
Aortic valve replacement and ascending
aortic arch repair
Alive at 12 months
Placement of proximal extension graft
following left carotid-subclavian
surgical bypass
Alive at 12 months
observed on preprocedural computed tomography (CT) imaging per core
ere not successful. The use of a molding balloon within the bare dissection
al disruption, which extended to the celiac artery and caused difficulty in
in this patient, and persistent false lumen perfusion was through a secondary
may also have contributed to the component separation.y int
a
y was
rtery w
intim
ervednvestigational device exemption studies, in which com-
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Volume 55, Number 3 Lombardi et al 637mercially available endografts were used in patients present-
ing with malperfusion and rupture only. In the current
study, 77.5% of the patients presented with malperfusion or
impending rupture, with a 30-day mortality rate of 6.5%
Fig 7. Diameter and area measurements (least square m
false lumen along the dissected aorta at preprocedure, po
for aorta at the right renal arteries and at the left renal a
artery.
Table VII. Status of false lumen
Timepoint
Thoracic
aorta
% (n/N)
Abdominal aorta
% (n/N)
Preprocedure
Patent 38.5 (15/39) 62.5 (25/40)
Partially thrombosed 61.5 (24/39) 35.0 (14/40)
Completely thrombosed 0 (0/39) 0 (0/40)
Not assessed n/a 2.5 (1/40)
Postprocedure
Patent 0 (0/34) 44.1 (15/34)
Partially thrombosed 94.1 (32/34) 52.9 (18/34)
Completely thrombosed 5.9 (2/34) 2.9 (1/34)
One month
Patent 0 (0/32) 22.6 (7/31)
Partially thrombosed 81.3 (26/32) 74.2 (23/31)
Completely thrombosed 18.8 (6/32) 3.2 (1/31)
Six months
Patent 0 (0/31) 34.5 (10/29)
Partially thrombosed 80.6 (25/31) 62.1 (18/29)
Completely thrombosed 19.4 (6/31) 3.4 (1/29)
Twelve months
Patent 0 (0/32) 15.6 (5/32)
Partially thrombosed 68.8 (22/32) 81.3 (26/32)
Completely thrombosed 31.3 (10/32) 3.1 (1/32)
n/a, Not assessed.
Based on qualitative assessment of thoracic and abdominal false lumen
segments as patent (evidence of contrast without evidence of thrombus),
partially thrombosed (evidence of both contrast and thrombus), or com-
pletely thrombosed (evidence of thrombus without evidence of contrast).(two of 31) for this patient subset. In the acute phase aohort, 18 patients who presented in this fashion had a
0-day mortality of 5.6% (1 of 18).
Inclusion criteria in this study were designed to include
ailure with medical therapy and ominous signs of impend-
ng rupture. Initial maximum transaortic diameter 40 to
5 mm has been demonstrated to be an independent
redictor of aortic enlargement in the chronic phase.12,13
e felt that early treatment for patients with transaortic
iameter 40 mm or early rapid growth may minimize
arly and late complications recognized in the literature.
one of the patients who were treated for these indications
n this series had aneurysmal progression of the thoracic
orta. Additionally, patients with persistent pain or persis-
ent hypertension refractory to maximum medical therapy
re at significant risk for aortic rupture or dissection pro-
ression. A recent review of the International Registry of
ortic Dissection revealed a startling in-hospital mortality
f 35.6% following only medical treatment in patients with
efractory pain and/or hypertension compared to 1.5% in
hose with no pain and good control of their blood pres-
ure.14 Ultimately, the guidelines set forth by the vast body
f literature on this subject should be weighed along with
ound clinical judgment.
Seven different device combinations were used in this
tudy, illustrating the adaptability of the modular dissection
ystem to different needs among this group of patients. The
ajority of patients (31 of 40; 77.5%) received only one
X2 stent graft to cover the primary entry tears. Extensive
tent graft coverage of thoracic aorta has been shown to
ncrease the risk of spinal cord ischemia.15 The amount of
roximal stent graft coverage was considered minimal,
hereby preserving intercostal flow within the thoracic
stimated from a general linear model) of true lumen and
cedure, and 12-month follow-up. Note that the curves
s are essentially overlapping. SMA, Superior mesentericeans e
stpro
rterieorta, while the remaining true lumen was supported by the
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(2.5%) may reflect the benefit of this strategy.
Performance of the dissection stent in the setting of
obstruction was demonstrated by augmentation of true
lumen diameter and flow. Narrowed abdominal aortic true
lumens were provided a quick and often vital re-expansion
(Fig 8). Placement of the dissection stent also facilitates
subsequent intervention of malperfused branch vessels.
Branch vessel hypoperfusion was reversed after selective
branch artery stent placement in nine patients (23%) during
the initial procedure. The expansion of the true lumen
allows for reapproximation and realignment of the intimal
orifice of the obstructed vessel, and the dissection stent’s
open design accommodates relatively easy access and can-
nulation of branch vessels through its interstices. If the
need arises to completely thrombose the false lumen
acutely or in the chronic setting, bridging the true lumen
and target vessels with a covered stent remains an option.
Notable complications resulting from placement of the
dissection system were strokes and retrograde dissection;
Fig 8. Imaging examples of true lumen expansion in the
of follow-up (B).most occurred within 30 days of the initial procedure. For che three patients (7.5%) who experienced strokes, a retro-
pective review of the head CT and/or magnetic resonance
maging were performed by an independent neuroradiolo-
ist. Although all three patients had LSA coverage, this was
ot thought to have contributed to the stroke because
mboli were observed in both the anterior and posterior
irculation. The distribution of infarcts suggested the pos-
ibility of procedural or technique-related factors. Never-
heless, it has been recommended that investigative sites
ollow the recently published SVS guidelines for the man-
gement of the LSA during thoracic endovascular aortic
epair.16 Presence of pre-existing hypertensive encephalo-
athy and severe intracranial atherosclerosis was found in
wo patients, and dissection in the region of the left com-
on carotid artery was present in the third patient (who
lso experienced retrograde progression of dissection). In-
errogation of the thoracic aorta at the level of or proximal
o the LSA, especially in patients with pre-existing cerebro-
ascular conditions, can result in emboli formation and
ubsequent stroke. To minimize the risk of stroke, prepro-
minal aorta (A) and aortic remodeling during the courseabdoedure imaging should be assessed carefully for the most
r
s
e
i
t
l
t
a
p
I
t
i
J
a
A
C
A
D
W
C
F
S
O
O
R
JOURNAL OF VASCULAR SURGERY
Volume 55, Number 3 Lombardi et al 639proximal extent of dissection and great caution exercised to
ensure adequate device flushing and careful manipulation
of the wire guide and delivery system.
In two of the three patients with retrograde dissection,
the stent graft was placed with inadequate proximal landing
zones. Furthermore, in one of these two patients, the stent
graft was placed in the dissected, mid-descending thoracic
aorta and migrated caudally. These findings emphasize a
minimum landing zone of 20 mm of healthy aorta, with
consideration to landing the stent graft as far proximal to
the dissection as possible. In the third patient, refractory
hypertension after the procedure may have contributed to
retrograde progression of dissection. In this patient, use of
a molding balloon at the junction of stent graft and dissec-
tion stent may have also contributed to retrograde propa-
gation of the dissection.
Favorable remodeling of the aorta was evident by early
true lumen expansion and concomitant false lumen regres-
sion. The improved outcomes associated with favorable
aortic remodeling and false lumen thrombosis after endo-
vascular repair of cTBAD have been echoed in many re-
ports.17 The significance of aortic remodeling in the long
term is still unknown, but such remodeling may predict
long-term success after endograft exclusion, particularly
with regards to late aneurysm formation.18 False lumen
thrombosis has been observed to provide the greatest free-
dom from dissection-related mortality in the long term.19
Indeed, some investigators have preferred to extend the
proximal endograft to the celiac level for additional false
lumen thrombosis. However, persistent flow in the false
lumen after endograft therapy has yet to demonstrate un-
favorable outcomes.
Of note, complete thrombosis of both the thoracic and
abdominal false lumen segments in all patients was not
expected as the study protocol did not require exclusion of
all sources of flow to the false lumen, which was left to
physician discretion. There appeared a slight but not statis-
tically significant increase in the false lumen size in the
visceral segment of the aorta between postprocedure and
12 months, which likely corresponds to continuous false
lumen perfusion via either collateral sources or secondary
tears in some patients. The significance of this observation
is still unknown, but this subset of patients may require
more aggressive therapy for false lumen exclusion to pre-
vent aneurysm formation.
In conclusion, endovascular therapy for cTBAD has
been widely accepted as the treatment of choice for patients
with favorable anatomy as defined by the study’s anatomic
inclusion/exclusion criteria. The initial results presented
here complement a rather robust experience in the litera-
ture with a two-component device that extends a surgeon’s
ability to directly treat a dissected aorta over the visceral
segment and beyond. Placement of the dissection stent has
allowed for true lumen expansion and mitigation of persis-
tent dynamic obstruction of branch vessels via realignment
and reapproximation of the delaminated segments, while
preserving options for branch vessel reinterventions. Limi-
tations of this study included the small sample size andelatively short follow-up. Long-term follow-up is neces-
ary to completely understand the disease process after
ndovascular intervention as well as the true benefit of the
ntervention. Furthermore, because no clear endpoint in
herapy has been defined for patients with persistent false
umen flow, longer-term data are needed to fully evaluate
he treatment strategy in this group. However, the encour-
ging results presented here have validated the safety and
erformance of the device for further investigation.
The authors thank the following individuals from MED
nstitute, Inc, a Cook Group Company, for their contribu-
ions to the manuscript: Qing Zhou, PhD, provided writ-
ng assistance during manuscript development; and Feiyi
ia, PhD, and Chyon-Hwa Yeh, PhD, performed statistical
nalyses.
UTHOR CONTRIBUTIONS
onception and design: JL, RPC, CN, PB
nalysis and interpretation: JL, RPC, CN, RC, OT, AL,
PM, PB
ata collection: JL, RPC, CN, RC, OT, AL, PM, PB
riting the article: JL, RPC, PB
ritical revision of the article: JL, RPC, CN, RC, OT, AL,
PM, PB
inal approval of the article: JL, RPC, CN, RC, OT, AL,
PM, PB
tatistical analysis: PB
btained funding: JL, PB
verall responsibility: JL
EFERENCES
1. Dake MD. Endovascular stent-graft management of thoracic aortic
diseases. Eur J Radiol 2001;39:42-9.
2. Umaña JP, Miller DC, Mitchell RS. What is the best treatment for
patients with acute type B aortic dissections–medical, surgical, or endo-
vascular stent-grafting? Ann Thorac Surg 2002;74:S1840-3; discussion
S1857-63.
3. Eggebrecht H, Nienaber CA, Neuhäuser M, Baumgart D, Kische S,
Schmermund A, et al. Endovascular stent-graft placement in aortic
dissection: a meta-analysis. Eur Heart J 2006;27:489-98.
4. Fattori R, Tsai TT, Myrmel T, Evangelista A, Cooper JV, Trimarchi S,
et al. Complicated acute type B dissection: is surgery still the best
option? A report from the International Registry of Acute Aortic Dis-
section. JACC Cardiovasc Interv 2008;1:395-402.
5. Mossop PJ, McLachlan CS, Amukotuwa SA, Nixon IK. Staged endo-
vascular treatment for complicated type B aortic dissection. Nat Clin
Pract Cardiovasc Med 2005;2:316-21; quiz 322.
6. Nienaber CA, Kische S, Zeller T, Rehders TC, Schneider H, Lorenzen
B, et al. Provisional extension to induce complete attachment after
stent-graft placement in type B aortic dissection: the PETTICOAT
concept. J Endovasc Ther 2006;13:738-46.
7. Melissano G, Bertoglio L, Kahlberg A, Baccellieri D, Marrocco-
Trischitta MM, Calliari F, et al. Evaluation of a new disease-specific
endovascular device for type B aortic dissection. J Thorac Cardiovasc
Surg 2008;136:1012-8.
8. Matsumura JS, Cambria RP, Dake MD, Moore RD, Svensson LG,
Snyder S; TX2 Clinical Trial Investigators. International controlled
clinical trial of thoracic endovascular aneurysm repair with the Zenith
TX2 endovascular graft: 1-year results. J Vasc Surg 2008;47:247-57;
discussion 257.
9. White RA, Miller DC, Criado FJ, Dake MD, Diethrich EB, Greenberg
RK, et al. Report on the results of thoracic endovascular aortic repair for
acute, complicated, type B aortic dissection at 30 days and 1 year from
11
1
1
S
JOURNAL OF VASCULAR SURGERY
March 2012640 Lombardi et ala multidisciplinary subcommittee of the Society for Vascular Surgery
Outcomes Committee. J Vasc Surg 2011;53:1082-90.
10. Virtue Registry Investigators. The VIRTUE Registry of type B thoracic
dissections–study design and early results. Eur J Vasc Endovasc Surg
2011;41:159-66.
11. Xu SD, Huang FJ, Yang JF, Li ZZ, Wang XY, Zhang ZG, et al.
Endovascular repair of acute type B aortic dissection: early and mid-
term results. J Vasc Surg 2006;43:1090-5.
12. Kunishige H, Myojin K, Ishibashi Y, Ishii K, Kawasaki M, Oka J.
Predictors of surgical indications for acute type B aortic dissection based
on enlargement of aortic diameter during the chronic phase. Jpn
J Thorac Cardiovasc Surg 2006;54:477-82.
13. Marui A, Mochizuki T, Mitsui N, Koyama T, Kimura F, Horibe M.
Toward the best treatment for uncomplicated patients with type B acute
aortic dissection: a consideration for sound surgical indication. Circu-
lation 1999;100(19 Suppl):II275-80.
14. Trimarchi S, Eagle KA, Nienaber CA, Pyeritz RE, Jonker FH, Suzuki T,
et al. Importance of refractory pain and hypertension in acute type B
aortic dissection: insights from the International Registry of Acute
Aortic Dissection (IRAD). Circulation 2010;122:1283-9.15. Feezor RJ, Martin TD, Hess PJ Jr, Daniels MJ, Beaver TM, Klodell CT,
et al. Extent of aortic coverage and incidence of spinal cord ischemia aafter thoracic endovascular aneurysm repair. Ann Thorac Surg
2008;86:1809-14; discussion 1814.
6. Matsumura JS, Lee WA, Mitchell RS, Farber MA, Murad MH, Lums-
den AB, et al. The Society for Vascular Surgery Practice Guidelines:
management of the left subclavian artery with thoracic endovascular
aortic repair. J Vasc Surg 2009;50:1155-8.
7. Conrad MF, Crawford RS, Kwolek CJ, Brewster DC, Brady TJ, Cam-
bria RP. Aortic remodeling after endovascular repair of acute compli-
cated type B aortic dissection. J Vasc Surg 2009;50:510-7.
8. Conrad MF, Ergul EA, Patel VI, Paruchuri V, Kwolek CJ, Cambria RP.
Management of diseases of the descending thoracic aorta in the endo-
vascular era: a Medicare population study. Ann Surg 2010;252:603-10.
9. Bernard Y, Zimmermann H, Chocron S, Litzler JF, Kastler B, Etievent
JP, et al. False lumen patency as a predictor of late outcome in aortic
dissection. Am J Cardiol 2001;87:1378-82.
ubmitted Jul 13, 2011; accepted Oct 4, 2011.
Additional material for this article may be found online
t www.jvascsurg.org.
sient ischemic attack.
JOURNAL OF VASCULAR SURGERY
Volume 55, Number 3 Lombardi et al 640.e1Table IV, online only. Percentage of patients experiencin
Category
Cardiovascular
Arrhythmia (requiring treatment or new treatment)
Refractory hypertension
Pulmonary
Pulmonary event requiring tracheostomy or chest tube
Ventilation 24 hours
Re-intubation
Pleural effusion requiring treatment
Pulmonary edema requiring antibiotics
Pneumonia requiring antibiotics
Supplemental O2 at discharge
Renal
Renal failure requiring dialysis
Serum creatinine rise 30% above baseline resulting in
a persistent value 176.8 mol/L
Gastrointestinal
GI bleeding requiring treatment
GI infection requiring treatment
Paralytic ileus 4 days
Neurologic
Stroke
TIA
Paraplegia
Paraparesis/spinal cord shock
Vascular
Postprocedure transfusion
Retrograde dissection
Pseudoaneurysm requiring surgical repair
Hematoma requiring receipt of blood products
DVT
Aneurysm leak/rupture
Wound
Wound infection requiring antibiotic treatment
Wound breakdown requiring debridement
DVT, Deep venous thrombosis; GI, gastrointestinal; O2, oxygen; TIA, trang morbid events by category
0-30 days 31-365 days
7.5% (3/40) 2.6% (1/38)
10.0% (4/40) 2.6% (1/38)
12.5% (5/40) 2.6% (1/38)
12.5% (5/40) 0% (0/38)
2.5% (1/40) 5.3% (2/38)
10.0% (4/40) 0% (0/38)
5.0% (2/40) 0% (0/38)
10.0% (4/40) 2.6% (1/38)
0% (0/40) 2.6% (1/38)
12.5% (5/40) 2.6% (1/38)
5.0% (2/40) 0% (0/38)
2.5% (1/40) 0% (0/38)
2.5% (1/40) 0% (0/38)
5.0% (2/40) 0% (0/38)
7.5% (3/40) 0% (0/38)
2.5% (1/40) 0% (0/38)
2.5% (1/40) 0% (0/38)
2.5% (1/40) 0% (0/38)
27.5% (11/40) 0% (0/38)
5.0% (2/40) 2.6% (1/38)
2.5% (1/40) 0% (0/38)
2.5% (1/40) 0% (0/38)
2.5% (1/40) 0% (0/38)
2.5% (1/40) 2.6% (1/38)
7.5% (3/40) 0% (0/38)
2.5% (1/40) 0% (0/38)
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March 2012640.e2 Lombardi et alFig 6, online only. Depiction of entry flow definitions. Entry
flow was defined as false lumen flow through the primary entry tear
around the proximal or distal end of the stent graft (type I,
depicted in blue), via collateral vessels through the primary tear
(type II, depicted in red), between joints of the covered compo-
nents or through defects in the graft material (type III), or due to
graft fabric porosity (type IV). The entry flow definitions have been
expanded to describe flow from collateral vessels directly into the
false lumen as “collateral” (depicted in yellow) and flow from the
true lumen into the false lumen through secondary tears as
“through secondary tear” (depicted in green).able VI online only. Entry flow by type at
xamination period
xamination period % (n/N)
ostprocedure
Type I proximal 2.9 (1/35)
Type I distal 0 (0/35)
Type II 14.3 (5/35)
Type III 0 (0/35)
Type IV 0 (0/35)
Type unknown 0 (0/35)
Collateral 82.9 (29/35)
Through secondary tear 20.0 (7/35)
All types 0 (0/35)
ne month
Type I proximal 3.1 (1/32)
Type I distal 0 (0/32)
Type II 9.4 (3/32)
Type III 0 (0/32)
Type IV 0 (0/32)
Type unknown 0 (0/32)
Collateral 87.5 (28/32)
Through secondary tear 37.5 (12/32)
All types 0 (0/32)
ix months
Type I proximal 3.1 (1/32)
Type I distal 0 (0/32)
Type II 0 (0/32)
Type III 0 (0/32)
Type IV 0 (0/32)
Type unknown 3.1 (1/32)
Collateral 90.6 (29/32)
Through secondary tear 31.3 (10/32)
All types 0 (0/32)
welve months
Type I proximal 3.1 (1/32)
Type I distal 0 (0/32)
Type II 0 (0/32)
Type III 0 (0/32)
Type IV 0 (0/32)
Type unknown 3.1 (1/32)
Collateral 96.9 (31/32)
Through secondary tear 50.0 (16/32)
All types 0 (0/32)
